CRISPR Therapeutics CRSP Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.46M+68.6% | $864K-97.6% | $889K+47.7% | $892K+72.5% | $865K+71.6% | ||
| $68.57M-5.4% | $83.53M+16.4% | $58.9M-28.3% | $69.89M-12.8% | $72.48M-4.8% | ||
| $17.18M-11.0% | $18.4M+1.5% | $16.93M-2.8% | $18.92M-2.9% | $19.3M+7.5% | ||
| $4.32M-8.8% | $5.66M+16.9% | $4.43M-6.5% | $4.65M-4.0% | $4.74M-2.0% | ||
| $131.71M-11.8% | $155.63M+55.2% | $132.95M+20.1% | $230.22M+51.7% | $149.29M+5.8% | ||
| $131.71M-11.8% | $155.63M+55.2% | $132.95M+20.1% | $230.22M+51.7% | $149.29M+5.8% | ||
| -$130.25M+12.2% | -$154.76M-140% | -$132.06M-19.9% | -$229.32M-51.6% | -$148.42M-5.6% | ||
| -8,933.3%+8,226pp | -17,912.5%-17,732pp | -14,854.8%+3,439pp | -25,709%+3,548pp | -17,158.8%+10,735pp | ||
| $8.16M-39.8% | $24.77M-11.5% | $26.24M+4.7% | $22.07M-15.6% | $13.54M-45.2% | ||
| -$122.09M+9.5% | -$130M-255% | -$105.82M-24.4% | -$207.26M-65.6% | -$134.89M-16.4% | ||
| $839K-24.3% | $614K-12.3% | $619K-29.3% | $1.29M+0.4% | $1.11M+53.2% | ||
| -$122.93M+9.6% | -$130.61M-250% | -$106.44M-23.9% | -$208.55M-65.0% | -$136M-16.6% | ||
| -8,431.5%+7,291pp | -15,117.2%-15,013pp | -11,973.1%+2,303pp | -23,379.9%+1,070pp | -15,722.1%+7,411pp | ||
| -$1.28+19.0% | -$1.35-221% | -$1.17-15.8% | -$2.40-61.1% | -$1.58-10.5% | ||
| -$1.28+19.0% | -$1.35-221% | -$1.17-15.8% | -$2.40-61.1% | -$1.58-10.5% | ||
| 96.1M+11.8% | 89.9M+6.6% | 91.3M+7.1% | 87.1M+2.5% | 85.9M+5.1% | ||
| 96.1M+11.8% | 89.9M+6.6% | 91.3M+7.1% | 87.1M+2.5% | 85.9M+5.1% | ||
| $45.95M-20.1% | $53.7M+416% | $57.12M+412% | $45.15M-13.4% | $57.51M+22.4% | ||
| -$129.69M+3.0% | -$130.78M-184% | -$105.5M-45.5% | -$208.64M-63.3% | -$133.7M-11.4% | ||
| -$13.02M-130% | $4.42M+156% | $12.18M+132% | —— | $43M+355% | ||
| -$0+100% | —— | —— | —— | -$25M+87.5% | ||
| -$199K+98.1% | $13.55M+35.7% | —— | —— | -$10.54M-2,340% | ||
| $247K-61.0% | -$3.85M-2,089% | -$212K— | $93K+104% | $634K+121% | ||
| -$32K-178% | $1K+101% | -$28K-137% | $80K+3,900% | $41K+473% | ||
| -$6.73M-399% | $0+100% | $973K-92.7% | -$174K+86.9% | $2.25M+165% | ||
| $8.16M-39.8% | $24.77M-11.5% | $26.24M+4.7% | $22.07M-15.6% | $13.54M-45.2% | ||
| $504K+145% | $517K+104% | $74K-66.2% | $117K-83.5% | $206K-71.4% | ||
| $1.46M+68.6% | $864K-97.6% | $889K+47.7% | $892K+72.5% | $865K+71.6% | ||
| $16.32M-19.2% | $18.08M-17.6% | $16.6M-22.9% | $17.61M-25.6% | $20.21M+4.2% | ||
| -$130.25M+12.2% | -$154.76M-140% | -$132.06M-19.9% | -$229.32M-51.6% | -$148.42M-5.6% | ||
| -$125.93M+12.4% | -$149.1M-150% | -$127.63M-21.1% | -$224.68M-53.5% | -$143.69M-5.8% | ||
| -$125.93M+12.4% | -$149.1M-150% | -$127.63M-21.1% | -$224.68M-53.5% | -$143.69M-5.8% | ||
| -8,637.1%+7,974pp | -17,257.3%-17,090pp | -14,356.1%+3,151pp | -25,187.8%+3,132pp | -16,611.3%+10,324pp | ||
| -$130.25M+12.2% | -$154.76M-140% | -$132.06M-19.9% | -$229.32M-51.6% | -$148.42M-5.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is CRISPR Therapeutics's revenue?
- CRISPR Therapeutics (CRSP) generated $4.1M in revenue over the trailing twelve months, down 89.1% year over year.
- Is CRISPR Therapeutics profitable?
- CRISPR Therapeutics is not currently profitable: it reported a net loss of $568.5M over the trailing twelve months, a -13856.5% net margin.
- What is CRISPR Therapeutics's earnings per share?
- CRISPR Therapeutics's diluted EPS over the trailing twelve months is $-6.20.
- Where does CRISPR Therapeutics's income statement data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
